Gapping up
In reaction to strong earnings/guidance:
- AVID +15.3%, TGT +9.3%, QIWI +4.2%, MFGP +3.8%, LOW +3.6%, CURLF +1.5%
Other news:
- ARAV +215.5% (new positive data from the ongoing Phase 1b portion of the Phase 1b/2 clinical trial of AVB-500 in platinum-resistant recurrent ovarian cancer patients)
- BRY +24.4% (attributed to comments from California Governor Gavin Newsom that he has ordered a halt to new fracking permits)
- CRC +12.9% (does not expect yesterday's proposal by the California Department of Conservation to have a significant effect on its production, plans or reserves)
- MYOV +10.3% (continued strength)
- FLNT +9.2% (authorizes the repurchase of up to $5 mln shares of common stock)
- BCRX +6.7% (Point72 increases passive stake)
- ENDP +6.1% (announces FDA acceptance of BLA for collagenase clostridium histolyticum in patients with cellulite)
- STNG +3.5% (announced its President Robert Bugbee purchased call options on 200,000 common shares (or 2,000 call option contracts) with strike price of $32.00 and an expiration of January 2020 for the consideration of $450,000)
- SAFE +2.1% (upsizes offering by 1 mln shares and prices offering of 3 mln shares of common stock at $34.00 per share)
Analyst comments:
- XCUR +8.8% (initiated with a Buy at Guggenheim)
- CTMX +8.7% (initiated with a Buy at Guggenheim)
- I +8.4% (upgraded to Outperform from Mkt Perform at Raymond James)
- PAYC +0.8% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)